Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Backside (NASDAQ:SRPT)


This text was written by

Biologics is a full-time healthcare investor who developed a ardour for biotech and life saving therapies after working within the medical area for years. His commerce focus is round modern corporations creating breakthrough therapies and/or prescription drugs with catalysts for potential acquisitions.

He’s the chief of the investing group Compounding Healthcare. Options of the group embrace: A number of mannequin healthcare portfolios, a weekly e-newsletter, a every day watchlist, and chat for dialogue and questions. Study extra.

Analyst’s Disclosure:I/now we have a useful lengthy place within the shares of SRPT both by means of inventory possession, choices, or different derivatives. I wrote this text myself, and it expresses my very own opinions. I’m not receiving compensation for it (apart from from Looking for Alpha). I’ve no enterprise relationship with any firm whose inventory is talked about on this article.

Looking for Alpha’s Disclosure: Previous efficiency is not any assure of future outcomes. No suggestion or recommendation is being given as as to if any funding is appropriate for a specific investor. Any views or opinions expressed above could not replicate these of Looking for Alpha as an entire. Looking for Alpha is just not a licensed securities supplier, dealer or US funding adviser or funding financial institution. Our analysts are third occasion authors that embrace each skilled traders and particular person traders who might not be licensed or licensed by any institute or regulatory physique.



Source link

Related articles

The streamers are preventing over Halloween

The Toronto Worldwide Movie Pageant is a spot to go to see the way forward for movie, however this 12 months it additionally supplied a glimpse at what's coming very quickly within the...

7 takeaways from the September FOMC

A brand new mountaineering cycle, alongside an upward revision to the Fed's longer run impartial price estimate, factors to a better for longer price atmosphere than markets had been pricing coming into the...

Payward Needs to Put US-Regulated Perpetual Futures on Hyperliquid

Payward plans to deliver US-regulated perpetual futures to Hyperliquid’s on-chain order guide. The markets would use Hyperliquid’s infrastructure, however entry, clearing and administration would stick with Payward’s regulated Bitnomial and NinjaTrader entities.London's buying...

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Name Transcript

Unknown Government Good morning, everybody. Thanks for becoming a member of us right here in New York on the webcast and in individual. At present, Dwight Egan, Chief Government Officer of Co-Diagnostics,...
spot_img

Latest articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP2Social Auto Publish Powered By : XYZScripts.com